Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Significant Growth in Short Interest

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) saw a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 576,400 shares, a growth of 149.0% from the January 31st total of 231,500 shares. Based on an average trading volume of 281,000 shares, the days-to-cover ratio is currently 2.1 days.

Oramed Pharmaceuticals Trading Down 0.5 %

Shares of Oramed Pharmaceuticals stock traded down $0.01 on Friday, reaching $2.09. 58,677 shares of the stock were exchanged, compared to its average volume of 323,366. The firm has a market capitalization of $84.25 million, a PE ratio of 19.00 and a beta of 1.66. Oramed Pharmaceuticals has a 1-year low of $2.00 and a 1-year high of $3.48. The business has a fifty day moving average price of $2.31 and a two-hundred day moving average price of $2.36.

Analyst Upgrades and Downgrades

Separately, StockNews.com lowered shares of Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, February 19th.

Institutional Trading of Oramed Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. World Equity Group Inc. purchased a new position in Oramed Pharmaceuticals in the fourth quarter worth $48,000. XTX Topco Ltd grew its stake in shares of Oramed Pharmaceuticals by 59.7% during the 3rd quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 9,242 shares during the period. Marquette Asset Management LLC purchased a new position in shares of Oramed Pharmaceuticals in the 4th quarter valued at about $81,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Oramed Pharmaceuticals in the third quarter valued at about $272,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Oramed Pharmaceuticals by 143.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 70,190 shares during the period. 12.73% of the stock is currently owned by hedge funds and other institutional investors.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.